查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1494746

2030 年胰臟癌市场预测：按治疗类型、诊断工具、最终用户和地区进行的全球分析

Pancreatic Cancer Market Forecasts to 2030 - Global Analysis By Treatment Type, Diagnostic Tool (Computerized Tomography Scans, Magnetic Resonance Imaging, Positron Emission Tomography Scans and Other Diagnostic Tools), End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球胰臟癌市场规模为 34.2 亿美元，预计预测期内复合年增长率为 17.8%，到 2030 年将达到 91.3 亿美元。

胰臟癌是一种在胰臟组织中发生的恶性，胰臟是位于胃后面的器官。其特征是胰臟细胞异常且不受控制地生长，导致肿瘤的形成。胰臟癌通常难以早期发现，导致其死亡率很高。症状可能直到疾病晚期才会出现，可能包括腹痛、黄疸、不明原因的体重减轻和消化器官系统问题。

根据美国癌症协会估计，到 2023 年，预计将有约 64,050 人被诊断出患有胰腺癌，约 50,550 人将死于胰腺癌。

病人支持团体的积极参与

患者倡导团体的积极参与透过提高意识、推动研究倡议和影响政策变化，在加强胰腺癌市场方面发挥着至关重要的作用。这些组织是患者的强有力的倡导者，放大患者的声音并游说增加胰腺癌研究的资金和资源。透过他们的工作，患者倡导团体不仅提高公众对胰腺癌的认识，还动员对早期检测和创新治疗方法的支持。此外，我们还促进研究人员、医疗保健专业人员和製药公司之间的合作，以加速新治疗方法的开发并改善患者的治疗效果。

治疗费用高

高昂的治疗费用构成了患者获得治疗的主要障碍，也是胰臟癌市场的主要障碍。由于胰臟癌是一种复杂的疾病，治疗时间往往会延长，进一步加重了患者和医疗保健系统的经济负担。然而，高昂的医疗费用不仅阻碍患者及时寻求治疗，而且还导致医疗预算紧张，并限制了新治疗方法研发的资源。

提升手术技术

手术技术的进步正在显着推动胰臟癌市场的发展，带来更有效的治疗选择并改善患者的治疗效果。与传统开放性手术相比，腹腔镜和机器人辅助手术等微创手术可减少术后併发症、缩短恢復时间并提高患者舒适度。这些进步使外科医生能够更精确地进行复杂的切除术，并且对周围组织的损伤最小，从而提高患者的生存率和生活品质。

缺乏早期检测的生物标记

缺乏用于早期检测的可靠生物标记是胰臟癌市场发展的主要障碍。与其他癌症不同，生物标记可以帮助早期诊断，胰臟癌通常直到晚期才出现症状，这使得及时发现变得困难。因此，患者经常被诊断出患有已经转移的疾病，严重限制了治疗选择并降低了整体存活率。由于缺乏有效的生物标誌物，临床医生缺乏在早期、可治疗阶段识别胰臟癌的方法，阻碍了标靶治疗和个人化治疗方法的发展。

COVID-19 的影响：

虽然疫情加剧了创新治疗的紧迫性并加速了研究工作，但它也扰乱了病患照护和临床试验。将医疗资源转移到管理 COVID-19 上，导致癌症服务紧张，并延迟了许多胰腺癌患者的诊断和治疗开始。对不必要的医疗程序的限制以及更少的患者就诊医疗机构导致筛检和诊断程序减少，可能导致胰臟癌的漏诊或延迟诊断。然而，大流行刺激了远端医疗和远端监控解决方案的采用，为在 COVID-19 限制带来的挑战中继续患者护理和参与临床试验提供了途径。

预计放射线治疗产业在预测期内将是最大的

预计放射线治疗领域在预测期内将是最大的。这种治疗方法使用高能量辐射来破坏癌细胞并缩小肿瘤。对于胰臟癌，手术选择往往受到最终诊断或肿瘤位置的限制，放射线治疗正在成为重要的治疗选择。放射线治疗用于在手术前缩小肿瘤，使其更适合手术切除，并在手术后瞄准剩余的癌细胞。此外，放射线治疗通常与其他治疗方法（例如化疗）结合使用，以最大限度地发挥其疗效。

磁振造影（MRI）领域预计在预测期内将呈现最高的复合年增长率。

磁振造影（MRI）领域预计在预测期内复合年增长率最高。 MRI具有优良的软组织对比度，可以准确地显示胰臟及周围结构，有利于胰臟肿瘤的早期发现和准确分期。 MRI 是非侵入性的，不使用电离辐射，这使其特别有利于监测疾病进展和治疗效果。此外，扩散加权成像和动态造影MRI 等进步正在进一步提高胰臟癌检测的敏感度和特异性。

比最大的地区

据估计，亚太地区在估计期间占据胰腺癌市场的最大份额。有效的报销政策可以促进更多患者获得昂贵但可能挽救生命的治疗，例如化疗、放射线治疗和手术干预。透过确保医疗费用得到支付，这些政策鼓励医疗保健提供者采用先进的技术和治疗方法，并促进区域内胰腺癌患者护理品质的提高。此外，有利的报销政策激励製药公司投资于针对当地医疗需求的研发，从而推出新型治疗方法和诊断工具。

复合年增长率最高的地区：

预计亚太地区在估计和预测期内将实现盈利成长。透过严格的法律规范，政府确保製药公司在开发胰臟癌治疗方法时遵守高功效和安全标准。监管机构正在努力加快新治疗方法的核准流程，并确保亚太地区的患者能够及时获得尖端治疗方法。此外，监管促进了市场相关人员之间的透明度和公平竞争，透过以有竞争力的价格提供更广泛的治疗选择，最终使消费者受益。这些因素正在推动该地区的成长。

提供免费客製化：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第四章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球胰臟癌市场：依治疗类型

  • 放射治疗
  • 标靶药物治疗
  • 免疫疗法
  • 化疗
  • 其他治疗类型

第六章全球胰臟癌市场：依诊断工具分类

  • 电脑断层扫描 (CT) 扫描
  • 磁振造影(MRI)
  • 正子断层扫描 (PET) 扫描
  • 其他诊断工具

第七章全球胰臟癌市场：依最终用户分类

  • 诊断实验室
  • 医院
  • 其他最终用户

第八章全球胰臟癌市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第 10 章 公司概况

  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Midatech Pharma PLC
  • Eli Lilly and Company
  • Sun BioPharma, Inc
  • Oncolytics Biotech
  • Clovis Oncology
  • Polaris Pharmaceuticals, Inc
  • Pharmacyte Biotech Inc
  • Novartis International AG
Product Code: SMRC26261

According to Stratistics MRC, the Global Pancreatic Cancer Market is accounted for $3.42 billion in 2024 and is expected to reach $9.13 billion by 2030 growing at a CAGR of 17.8% during the forecast period. Pancreatic cancer is a malignant neoplasm that originates in the tissues of the pancreas, an organ located behind the stomach. It is characterized by the abnormal and uncontrollable growth of cells in the pancreas, leading to the formation of tumors. Pancreatic cancer is often difficult to detect in its early stages, which contributes to its high mortality rate. Symptoms may not manifest until the disease has progressed significantly, and they can include abdominal pain, jaundice, unexplained weight loss, and digestive issues.

According to the America's Cancer Society for pancreatic cancer, about 64,050 people will be diagnosed with pancreatic cancer in 2023 and estimation of around 50,550 people will die of pancreatic cancer.

Market Dynamics:

Driver:

Active involvement of patient advocacy groups

Active involvement of patient advocacy groups is playing a pivotal role in enhancing the Pancreatic Cancer Market by fostering awareness, driving research initiatives, and influencing policy changes. These groups serve as powerful advocates for patients, amplifying their voices and lobbying for increased funding and resources for pancreatic cancer research. Through their efforts, patient advocacy groups are not only raising public awareness about the disease but also mobilizing support for early detection methods and innovative treatments. Moreover, they facilitate collaboration among researchers, healthcare professionals, and pharmaceutical companies, accelerating the development of novel therapies and improving patient outcomes.

Restraint:

High treatment costs

High treatment costs significantly hinder the Pancreatic Cancer Market by posing a substantial barrier to access for patients. The complexity of the disease often requires prolonged treatment periods, further exacerbating financial burdens on patients and healthcare systems. However, the high costs not only deter patients from seeking timely medical care but also strain healthcare budgets, limiting the availability of resources for research and development of new therapies.

Opportunity:

Improvements in surgical techniques

Improvements in surgical techniques are significantly enhancing the pancreatic cancer market by offering more effective treatment options and better patient outcomes. Minimally invasive procedures, such as laparoscopic and robotic-assisted surgeries, have reduced postoperative complications, shortened recovery times, and improved patient comfort compared to traditional open surgeries. These advancements enable surgeons to perform complex pancreatic resections with greater precision and minimal damage to surrounding tissues, leading to improved survival rates and quality of life for patients.

Threat:

Lack of biomarkers for early detection

The absence of reliable biomarkers for early detection poses a significant obstacle in advancing the pancreatic cancer market. Unlike some other cancers where biomarkers aid in early diagnosis, pancreatic cancer often remains asymptomatic until it reaches advanced stages, making timely detection challenging. Consequently, patients are often diagnosed when the disease has already metastasized, severely limiting treatment options and reducing overall survival rates. Without effective biomarkers, clinicians lack the tools to identify pancreatic cancer in its initial stages when it's more treatable, hindering the development of targeted therapies and personalized treatment approaches.

Covid-19 Impact:

While the pandemic heightened the urgency for innovative treatments and accelerated research efforts, it also disrupted patient care and clinical trials. The diversion of healthcare resources towards managing Covid-19 strained cancer care services, leading to delayed diagnoses and treatment initiation for many pancreatic cancer patients. Restrictions on non-essential medical procedures and reduced patient visits to healthcare facilities resulted in a decline in screening and diagnostic procedures, potentially causing missed or delayed diagnoses of pancreatic cancer. However, the pandemic also prompted the adoption of telemedicine and remote monitoring solutions, offering some avenues for continued patient care and clinical trial participation amidst the challenges posed by Covid-19 restrictions.

The Radiation Therapy segment is expected to be the largest during the forecast period

Radiation Therapy segment is expected to be the largest during the forecast period. This therapy involves the use of high-energy radiation to destroy cancer cells and shrink tumors. In the case of pancreatic cancer, where surgical options are often limited due to late-stage diagnosis or tumor location, radiation therapy emerges as a crucial treatment modality. It can be employed preoperatively to shrink tumors, making them more manageable for surgical removal, or postoperatively to target any remaining cancer cells. Additionally, radiation therapy is often combined with other treatment modalities like chemotherapy to maximize its effectiveness.

The Magnetic Resonance Imaging (MRI) segment is expected to have the highest CAGR during the forecast period

Magnetic Resonance Imaging (MRI) segment is expected to have the highest CAGR during the forecast period. MRI offers superior soft tissue contrast, allowing for precise visualization of the pancreas and surrounding structures, facilitating early detection and accurate staging of pancreatic tumors. Its non-invasive nature and lack of ionizing radiation make it particularly advantageous for monitoring disease progression and treatment response. Moreover, advancements such as diffusion-weighted imaging and dynamic contrast-enhanced MRI have further improved the sensitivity and specificity of pancreatic cancer detection.

Region with largest share:

Asia Pacific region is estimated to hold the largest share of the Pancreatic Cancer Market over the extrapolated period of time. Effective reimbursement policies can facilitate broader patient access to costly yet potentially life-saving treatments such as chemotherapy, radiation therapy, and surgical interventions. By ensuring that healthcare costs are covered, these policies encourage healthcare providers to adopt advanced technologies and therapies, driving regional improvements in the quality of care for pancreatic cancer patients. Moreover, favorable reimbursement policies can incentivize pharmaceutical companies to invest in research and development efforts tailored to the region's specific healthcare needs, leading to the introduction of novel therapies and diagnostic tools.

Region with highest CAGR:

Asia Pacific region is projected to estimate the profitable growth during the forecasted period. Through stringent regulatory frameworks, governments are ensuring that pharmaceutical companies adhere to high standards of efficacy and safety in developing pancreatic cancer treatments throughout the region. Regulatory bodies are working towards expediting the approval process for new therapies, facilitating timely access to cutting-edge treatments for patients in the Asia Pacific region. Additionally, regulations promote transparency and fair competition among market players, which ultimately benefits consumers by offering a wider range of treatment options at competitive prices. These elements are boosting the regional growth.

Key players in the market

Some of the key players in Pancreatic Cancer market include Celgene Corporation, F. Hoffmann-La Roche AG, Midatech Pharma PLC, Eli Lilly and Company, Sun BioPharma, Inc, Oncolytics Biotech, Clovis Oncology, Polaris Pharmaceuticals, Inc, Pharmacyte Biotech Inc and Novartis International AG.

Key Developments:

In March 2023, Novartis is currently in Phase I of the clinical development of LGK-974 for metastatic pancreatic cancer. The phase transition success rate (PTSR) benchmark for moving into Phase II for Phase I drugs for Metastatic Pancreatic Cancer is 88%, according to GlobalData.

In December 2022, scientists developed the world's first early pancreatic cancer screening test, which utilizes worms to discover tumors. The test, which was initiated in Japan this month, claims to be 100% precise in detecting cancer and can trace it in its early stages.

In October 2022, Erasca, based extended its current collaboration with Pfizer to evaluate ERAS-007 when combined with Pfizer's Ibrance (palbociclib). Both biopharma will start clinical proof-of-concept research as part of the extended clinical trial collaboration and supply agreement.

In February 2022, A partnership between Eli Lilly and Company and UNICEF was announced with the goal of enhancing healthcare resources for the roughly 10 million children and adolescents with non-communicable diseases.

Treatment Types Covered:

  • Radiation Therapy
  • Targeted Drug Therapy
  • Immunotherapy
  • Chemotherapy
  • Other Treatment Types

Diagnostic Tools Covered:

  • Computerized Tomography (CT) Scans
  • Magnetic Resonance Imaging (MRI)
  • Positron Emission Tomography (PET) Scans
  • Other Diagnostic Tools

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pancreatic Cancer Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Radiation Therapy
  • 5.3 Targeted Drug Therapy
  • 5.4 Immunotherapy
  • 5.5 Chemotherapy
  • 5.6 Other Treatment Types

6 Global Pancreatic Cancer Market, By Diagnostic Tool

  • 6.1 Introduction
  • 6.2 Computerized Tomography (CT) Scans
  • 6.3 Magnetic Resonance Imaging (MRI)
  • 6.4 Positron Emission Tomography (PET) Scans
  • 6.5 Other Diagnostic Tools

7 Global Pancreatic Cancer Market, By End User

  • 7.1 Introduction
  • 7.2 Diagnostic Laboratories
  • 7.3 Hospitals
  • 7.4 Other End Users

8 Global Pancreatic Cancer Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Celgene Corporation
  • 10.2 F. Hoffmann-La Roche AG
  • 10.3 Midatech Pharma PLC
  • 10.4 Eli Lilly and Company
  • 10.5 Sun BioPharma, Inc
  • 10.6 Oncolytics Biotech
  • 10.7 Clovis Oncology
  • 10.8 Polaris Pharmaceuticals, Inc
  • 10.9 Pharmacyte Biotech Inc
  • 10.10 Novartis International AG

List of Tables

  • Table 1 Global Pancreatic Cancer Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 3 Global Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
  • Table 4 Global Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
  • Table 5 Global Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 6 Global Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 7 Global Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 8 Global Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
  • Table 9 Global Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
  • Table 10 Global Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 11 Global Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
  • Table 12 Global Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
  • Table 13 Global Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
  • Table 14 Global Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 15 Global Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 16 Global Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 17 North America Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
  • Table 18 North America Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 19 North America Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
  • Table 20 North America Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
  • Table 21 North America Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 22 North America Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 23 North America Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 24 North America Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
  • Table 25 North America Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
  • Table 26 North America Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 27 North America Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
  • Table 28 North America Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
  • Table 29 North America Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
  • Table 30 North America Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 31 North America Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 32 North America Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 33 Europe Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
  • Table 34 Europe Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 35 Europe Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
  • Table 36 Europe Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
  • Table 37 Europe Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 38 Europe Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 39 Europe Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 40 Europe Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
  • Table 41 Europe Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
  • Table 42 Europe Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 43 Europe Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
  • Table 44 Europe Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
  • Table 45 Europe Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
  • Table 46 Europe Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 47 Europe Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 48 Europe Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 49 Asia Pacific Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
  • Table 50 Asia Pacific Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 51 Asia Pacific Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
  • Table 52 Asia Pacific Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
  • Table 53 Asia Pacific Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 54 Asia Pacific Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 55 Asia Pacific Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 56 Asia Pacific Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
  • Table 57 Asia Pacific Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
  • Table 58 Asia Pacific Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 59 Asia Pacific Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
  • Table 60 Asia Pacific Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
  • Table 61 Asia Pacific Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
  • Table 62 Asia Pacific Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 63 Asia Pacific Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 64 Asia Pacific Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 65 South America Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
  • Table 66 South America Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 67 South America Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
  • Table 68 South America Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
  • Table 69 South America Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 70 South America Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 71 South America Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 72 South America Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
  • Table 73 South America Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
  • Table 74 South America Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 75 South America Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
  • Table 76 South America Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
  • Table 77 South America Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
  • Table 78 South America Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 79 South America Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 80 South America Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 81 Middle East & Africa Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
  • Table 82 Middle East & Africa Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 83 Middle East & Africa Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
  • Table 84 Middle East & Africa Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
  • Table 85 Middle East & Africa Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 86 Middle East & Africa Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 87 Middle East & Africa Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 88 Middle East & Africa Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
  • Table 89 Middle East & Africa Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
  • Table 90 Middle East & Africa Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 91 Middle East & Africa Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
  • Table 92 Middle East & Africa Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
  • Table 93 Middle East & Africa Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
  • Table 94 Middle East & Africa Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 95 Middle East & Africa Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 96 Middle East & Africa Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)